Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Victrex plc (VTXPF)
Thornton-Cleveleys, GB
Victrex plc operates globally, focusing on the development, manufacturing, and distribution of high-performance polymers through its various subsidiaries. The company structures its comprehensive operations across two primary segments: Industrial and Medical. A core focus involves pioneering PEEK and PAEK polymer solutions, which it supplies as both semi-finished products and fully engineered parts. Furthermore, Victrex delivers specialized material solutions specifically tailored for medical device manufacturers, offers a range of thermoplastic polymer components, and undertakes various trading activities. Its advanced materials find critical applications across diverse sectors such as automotive, aerospace, energy, industrial, manufacturing, electronics, and the broader medical field. Founded in 1993, Victrex plc maintains its corporate headquarters in Thornton-Cleveleys, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -0.06% | +6.14% | -3.35% | -16.00% | -3.35% | -14.25% | -56.53% | -75.07% | -62.56% | +32.50% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Chemicals - Specialty: +4.7%+0.1% Q1'26: +5.9% (vs Q1'24)
-
EPS growth Chemicals - Specialty: +13.2%+60.0% ★ Q1'26: -1,305.2% (vs Q1'24)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+11.7% Q1'26: +14.7% (vs Q1'24)
-
EBIT margin Chemicals - Specialty: +8.8%+12.2% ★ Q1'26: +12.9% (vs Q1'24)
-
ROIC Chemicals - Specialty: +5.6%+5.9% ★ Q1'26: +19.5% (vs Q1'24)
-
Share dilution Chemicals - Specialty: +0.1%+0.6% Q1'26: -1.0% (vs Q1'24)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×0.80× Q1'26: 0.61× (vs Q1'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Sep 2015 actual |
Sep 2016 actual |
Sep 2017 actual |
Sep 2018 actual |
Sep 2019 actual |
Sep 2020 actual |
Sep 2021 actual |
Sep 2022 actual |
Sep 2023 actual |
Sep 2024 actual |
Sep 2025 actual |
Sep 2026 7 Rev. Ana. 2 EPS Ana. |
Sep 2027 12 Rev. Ana. 1 EPS Ana. |
Sep 2028 5 Rev. Ana. 1 EPS Ana. |
Sep 2029 10 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
263.50M
est: 399.14M (-34.0%)
|
252.30M
est: 327.74M (-23.0%)
|
290.20M
est: 376.55M (-22.9%)
|
326.00M
est: 431.92M (-24.5%)
|
288.10M
est: 359.45M (-19.8%)
|
264.50M
est: 343.88M (-23.1%)
|
311.20M
est: 408.81M (-23.9%)
|
338.20M
est: 371.40M (-8.9%)
|
307.00M
est: 375.93M (-18.3%)
|
296.20M
est: 287.45M (+3.0%)
|
296.40M
est: 286.47M (+3.5%)
|
303.44M
285.87M – 321.00M
+5.9% YoY
|
317.61M
309.50M – 332.51M
+4.7% YoY
|
334.78M
322.57M – 349.18M
+5.4% YoY
|
339.83M
327.44M – 354.46M
+1.5% YoY
|
| EBITDA |
119.50M
est: 109.42M (+9.2%)
|
116.20M
est: 89.84M (+29.3%)
|
129.00M
est: 103.23M (+25.0%)
|
142.90M
est: 118.40M (+20.7%)
|
122.10M
est: 98.54M (+23.9%)
|
84.50M
est: 94.27M (-10.4%)
|
114.60M
est: 112.07M (+2.3%)
|
109.60M
est: 101.81M (+7.6%)
|
94.70M
est: 103.05M (-8.1%)
|
48.50M
est: 78.80M (-38.5%)
|
61.10M
est: 78.53M (-22.2%)
|
83.18M
78.37M – 88.00M
+5.9% YoY
|
87.07M
84.84M – 91.15M
+4.7% YoY
|
91.77M
88.43M – 95.72M
+5.4% YoY
|
93.16M
89.76M – 97.17M
+1.5% YoY
|
| EBIT |
106.30M
est: 80.15M (+32.6%)
|
100.60M
est: 65.81M (+52.9%)
|
111.40M
est: 75.62M (+47.3%)
|
126.90M
est: 86.73M (+46.3%)
|
104.70M
est: 72.18M (+45.1%)
|
63.80M
est: 69.06M (-7.6%)
|
92.70M
est: 82.09M (+12.9%)
|
88.00M
est: 74.58M (+18.0%)
|
73.20M
est: 75.49M (-3.0%)
|
25.30M
est: 57.72M (-56.2%)
|
36.20M
est: 57.53M (-37.1%)
|
60.94M
57.41M – 64.46M
+5.9% YoY
|
63.78M
62.15M – 66.77M
+4.7% YoY
|
67.23M
64.78M – 70.12M
+5.4% YoY
|
68.24M
65.75M – 71.18M
+1.5% YoY
|
| Net Income |
83.50M
est: 85.60M (-2.4%)
|
82.50M
est: 82.64M (-0.2%)
|
99.50M
est: 100.01M (-0.5%)
|
110.60M
est: 114.78M (-3.6%)
|
92.40M
est: 95.03M (-2.8%)
|
54.20M
est: 68.00M (-20.3%)
|
73.20M
est: 76.59M (-4.4%)
|
76.20M
est: 83.50M (-8.7%)
|
61.70M
est: 67.62M (-8.8%)
|
17.20M
est: 50.45M (-65.9%)
|
27.80M
est: 37.91M (-26.7%)
|
36.12M
32.47M – 39.45M
-4.7% YoY
|
43.67M
41.60M – 46.11M
+20.9% YoY
|
50.24M
47.86M – 53.06M
+15.0% YoY
|
58.96M
56.16M – 62.26M
+17.3% YoY
|
| SGA |
61.90M
est: 91.95M (-32.7%)
|
58.40M
est: 75.50M (-22.7%)
|
72.70M
est: 86.75M (-16.2%)
|
81.10M
est: 99.50M (-18.5%)
|
70.70M
est: 82.81M (-14.6%)
|
66.40M
est: 79.22M (-16.2%)
|
71.90M
est: 94.18M (-23.7%)
|
86.00M
est: 85.56M (+0.5%)
|
63.30M
est: 86.60M (-26.9%)
|
71.00M
est: 66.22M (+7.2%)
|
65.40M
est: 65.99M (-0.9%)
|
69.91M
65.86M – 73.95M
+5.9% YoY
|
73.17M
71.30M – 76.60M
+4.7% YoY
|
77.12M
74.31M – 80.44M
+5.4% YoY
|
78.29M
75.43M – 81.66M
+1.5% YoY
|
| EPS |
0.98
est: 0.97 (+0.7%)
|
0.97
est: 0.94 (+3.2%)
|
1.16
est: 1.14 (+2.0%)
|
1.29
est: 1.31 (-1.2%)
|
1.07
est: 1.08 (-1.0%)
|
0.63
est: 0.77 (-18.5%)
|
0.84
est: 0.87 (-3.6%)
|
0.88
est: 0.95 (-7.4%)
|
0.70
est: 0.77 (-9.0%)
|
0.20
est: 0.57 (-65.1%)
|
0.31
est: 0.43 (-28.1%)
|
0.41
0.37 – 0.45
-4.7% YoY
|
0.50
0.47 – 0.52
+20.9% YoY
|
0.57
0.54 – 0.60
+15.0% YoY
|
0.67
0.64 – 0.71
+17.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-04-27 | B+ | 3/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| James Mathew Routh | Chief Executive Officer & Executive Director | 1M | — |
| Ian Clifford Melling | Chief Financial Officer & Executive Director | 835.5K | male |
| Jilly Atherton | Group Human Resource Director | — | female |
| John Devine | Managing Director for Medical | — | — |
| Michael Koch | Managing Director of Sustainable Solutions | — | male |
| Jane Brisley | General Counsel & Company Secretary | — | female |
| Andrew Hanson | Director of Investor Relations, Corporate Communications & ESG | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VTXPF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
